Overview

A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of steady-state (constant concentration of medication in the blood) TMC435 (150 mg, once a day) on the steady state pharmacokinetics (what the body does to the medication) of R- and S-methadone.
Phase:
Phase 1
Details
Lead Sponsor:
Tibotec Pharmaceuticals, Ireland
Treatments:
Methadone
Simeprevir